Clinical Trial Update: Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) [Phase 2]

View source ↗

Summary

Phase 2 open-label, multiple ascending dose study of ravulizumab (ALXN1210) in participants with paroxysmal nocturnal hemoglobinuria (PNH) has completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 2 | Status: COMPLETED | Results posted: 2019-02-18